As the number of psychedelic therapeutic clinical trials continues to increase, a deeper understanding of these trials, such as sponsor type, location, and phase, are reviewed.
Scope
- Non-industry sponsors outnumber industry sponsors for psychedelic therapy trials. They account for 58% of psychedelic therapy trials, with the largest margin of difference seen in 2021.
- Yale University is the leading non-industry sponsor while Johnson & Johnson is the leading industry sponsor.
- Central nervous system is by far the top therapy area for psychedelic therapy trials, tested in 92% of all psychedelic therapy trials. The top indication is depression.
- At the country level, the US leads with 88% of all North American studies, followed by China.
- Phase II trials of psychedelic therapies have outnumbered all other phases since 2013.
Reasons to Buy
- Identifies and analyzes psychedelic therapeutic clinical trials by multiple trial designs, such as trial start year, geographic distribution, phase and drug details.
- Examines the cause of the increase of psychedelic clinical trials.
- Gives reasons for certain trends seen in psychedelic trials.
- Breaks down trials by sponsor type and top sponsors.
- Looks at the virtual components used for psychedelic trials.
- Describes the leading drugs used in psychdelic trials.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Yale University
- Johnson & Johnson
- Shire Pharmaceuticals
- Pfizer
- Lykos
- UCB